<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Engene Holdings Inc. — News on 6ix</title>
<link>https://6ix.com/company/engene-holdings-inc</link>
<description>Latest news and press releases for Engene Holdings Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/engene-holdings-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d74dfa51cc36e475334a9a.webp</url>
<title>Engene Holdings Inc.</title>
<link>https://6ix.com/company/engene-holdings-inc</link>
</image>
<item>
<title>enGene Announces Name Change to enGene Therapeutics Inc.</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-announces-name-change-to-engene-therapeutics-inc-1</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-announces-name-change-to-engene-therapeutics-inc-1</guid>
<pubDate>Tue, 07 Apr 2026 12:00:00 GMT</pubDate>
<description>BOSTON & MONTREAL, April 07, 2026--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to "enGene Therapeutics Inc." effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongo</description>
</item>
<item>
<title>enGene Reports First Quarter 2026 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-reports-first-quarter-2026-financial-results-and-provides-business-update-2</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-reports-first-quarter-2026-financial-results-and-provides-business-update-2</guid>
<pubDate>Mon, 09 Mar 2026 11:00:00 GMT</pubDate>
<description>BOSTON & MONTREAL, March 09, 2026--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update.</description>
</item>
<item>
<title>enGene to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Fri, 20 Feb 2026 13:00:00 GMT</pubDate>
<description>BOSTON & MONTREAL, February 20, 2026--enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences:</description>
</item>
<item>
<title>enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026</guid>
<pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
<description>BOSTON & MONTREAL, February 04, 2026--enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET.</description>
</item>
<item>
<title>enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-announces-expanded-dollar125-million-debt-facility-with-hercules-capital-inc-2</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-announces-expanded-dollar125-million-debt-facility-with-hercules-capital-inc-2</guid>
<pubDate>Tue, 20 Jan 2026 22:35:00 GMT</pubDate>
<description>BOSTON & MONTREAL, January 20, 2026--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the "Loan Agreement") with two of its subsidiaries and Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"), as agent, for up to US$125 million. Access to the additional non-dilutive capital strengthens enGene’s balance sheet</description>
</item>
<item>
<title>enGene Reports Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-reports-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-reports-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 22 Dec 2025 21:03:00 GMT</pubDate>
<description>BOSTON & MONTREAL, December 22, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update.</description>
</item>
<item>
<title>enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engenes-detalimogene-selected-for-fda-manufacturing-pilot-program-to-support-manufacturing-readiness</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engenes-detalimogene-selected-for-fda-manufacturing-pilot-program-to-support-manufacturing-readiness</guid>
<pubDate>Tue, 02 Dec 2025 12:30:00 GMT</pubDate>
<description>BOSTON & MONTREAL, December 02, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as detalimogene and previously EG-70) to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. Detalimogene is a novel, investigational, non-viral gene therapy for pati</description>
</item>
<item>
<title>enGene to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-to-present-at-the-piper-sandler-37th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-to-present-at-the-piper-sandler-37th-annual-healthcare-conference</guid>
<pubDate>Tue, 25 Nov 2025 12:30:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET.</description>
</item>
<item>
<title>enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-announces-pricing-of-dollar130-million-public-offering-of-common-shares-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-announces-pricing-of-dollar130-million-public-offering-of-common-shares-and-pre-funded-warrants</guid>
<pubDate>Thu, 13 Nov 2025 05:27:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 13, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at an offering price of $8.4999 per pre-funded warrant, in each case, before underwriting discounts and commis</description>
</item>
<item>
<title>enGene Announces Proposed Public Offering of Common Shares</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-announces-proposed-public-offering-of-common-shares</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-announces-proposed-public-offering-of-common-shares</guid>
<pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 12, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an underwritten public offering of its common shares. All common shares to be sold in the offering will be offered by enGene. In addition, enGene intends to grant the underwriters a 30-day option to purchase up to a number of additional common shares equal to 15% of the total number of common shares sold</description>
</item>
<item>
<title>Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months</title>
<link>https://6ix.com/company/engene-holdings-inc/news/detalimogene-demonstrates-improved-complete-response-rate-of-62percent-at-6-months</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/detalimogene-demonstrates-improved-complete-response-rate-of-62percent-at-6-months</guid>
<pubDate>Tue, 11 Nov 2025 12:30:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 11, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene and previously EG-70) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without conc</description>
</item>
<item>
<title>enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-to-host-conference-call-to-provide-update-on-pivotal-cohort-of-legend-trial</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-to-host-conference-call-to-provide-update-on-pivotal-cohort-of-legend-trial</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 10, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a conference call and webcast tomorrow, November 11, 2025, at 8:00 a.m. ET to discuss new preliminary data from its pivotal cohort in the ongoing LEGEND trial of its novel, non-viral gene therapy candidate, detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with high-r</description>
</item>
<item>
<title>enGene Named a BioSpace 2026 Best Places to Work Winner</title>
<link>https://6ix.com/company/engene-holdings-inc/news/engene-named-a-biospace-2026-best-places-to-work-winner</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc/news/engene-named-a-biospace-2026-best-places-to-work-winner</guid>
<pubDate>Tue, 04 Nov 2025 18:35:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 04, 2025--enGene Holdings Inc. ("enGene" or the "Company") (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, today announced that BioSpace has named the company to its 2026 Best Places to Work. enGene is among 50 U.S. operating employers recognized as one of the most desirable workplaces in the life sciences industry.</description>
</item>
</channel>
</rss>